英文药名:Bydureon(EXENATIDE injection in pre-filled pen) 中文药名:艾塞那肽缓释剂注射用混悬液预充笔 生产厂家:Amylin Pharmaceuticals,Inc./Alkermes plc
2 Rate based on Bydureon spontaneous reports data. 3 Reactions were in the same frequency grouping in the exenatide twice-daily treatment group. 4 Rate based on Bydureon clinical trial database n=3,111 (including all completed long-term efficacy and safety studies). Description of selected adverse reactions Hypoglycaemia The incidence of hypoglycaemia was increased when Bydureon was used in combination with a sulphonylurea (15.9 % versus 2.2 %) (see section 4.4). To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea may be considered (see sections 4.2 and 4.4). Bydureon was associated with a significantly lower incidence of episodes of hypoglycaemia than insulin glargine in patients also receiving metformin therapy (3 % versus 19 %) and in patients also receiving metformin plus sulphonylurea therapy (20 % versus 42 %). Across all studies most episodes (96.8 % n=32) of hypoglycaemia were minor, and resolved with oral administration of carbohydrate. One patient was reported with major hypoglycaemia since he had a low blood glucose value (2.2 mmol/l) and requested assistance with oral carbohydrate treatment which resolved the event. Nausea The most frequently reported adverse reaction was nausea. In patients treated with Bydureon, generally 20 % reported at least one episode of nausea compared to 34 % of exenatide twice-daily patients. Most episodes of nausea were mild to moderate. With continued therapy, the frequency decreased in most patients who initially experienced nausea. The incidence of withdrawal due to adverse events during the 30-week controlled trial was 6 % for Bydureon-treated patients, 5 % for exenatide twice-dailytreated patients. The most common adverse events leading to withdrawal in either treatment group were nausea and vomiting. Withdrawal due to nausea or vomiting each occurred in < 1 % for Bydureon-treated patients and 1 % for exenatide twice daily treated patients. Injection site reactions Injection site reactions were observed more frequently in Bydureon-treated patients versus comparator treated patients (16 % versus range of 2-7 %) during the 6 month controlled phase of studies. These injection site reactions were generally mild and usually did not lead to withdrawal from studies. Patients may be treated to relieve symptoms, while continuing treatment. Subsequent injections should use a different site of injection each week. In post marketing experiences, cases with injection site abscesses and cellulitis have been reported. Small subcutaneous injection site nodules were observed very frequently in clinical trials, consistent with the known properties of poly (D,L-lactide co-glycolide) polymer microsphere formulations. Most individual nodules were asymptomatic, did not interfere with study participation and resolved over 4 to 8 weeks. Immunogenicity Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop antibodies to exenatide following treatment with Bydureon. In most patients who develop antibodies, antibody titres diminish over time. The presence of antibodies (high or low titres) is not predictive of glycaemic control for an individual patient. In clinical studies of Bydureon, approximately 45 % of patients had low titre antibodies to exenatide at study endpoint. Overall the percentage of antibody positive patients was consistent across clinical trials. Overall, the level of glycaemic control (HbA1c) was comparable to that observed in those without antibody titres. On average in the phase 3 studies, 12 % of the patients had higher titre antibodies. In a proportion of these the glycaemic response to Bydureon was absent at the end of the controlled period of studies; 2.6 % of patients showed no glucose improvement with higher titre antibodies while 1.6 % showed no improvement while antibody negative. Patients who developed antibodies to exenatide tend to have more injection site reactions (for example: redness of skin and itching), but otherwise similar rates and types of adverse events as those with no antibodies to exenatide. For Bydureon-treated patients, the incidence of potentially immunogenic injection site reactions (most commonly pruritus with or without erythema) during the 30-week and the two 26-week studies, was 9 %. These reactions were less commonly observed in antibody-negative patients (4 %) compared with antibody-positive patients (13 %), with a greater incidence in those with higher titre antibodies. Examination of antibody-positive specimens revealed no significant cross-reactivity with similar endogenous peptides (glucagon or GLP-1). Rapid weight loss In a 30-week study, approximately 3 % (n=4/148) of Bydureon-treated patients experienced at least one time period of rapid weight loss (recorded body weight loss between two consecutive study visits of greater than 1.5 kg/week). Increased heart rate A mean increase in heart rate (HR) of 2.6 beats per minute (bpm) from baseline (74 bpm) was observed in pooled Bydureon clinical studies. Fifteen percent of Bydureon treated patients had mean increases in HR of ≥10 bpm; approximately 5% to 10% of subjects within the other treatment groups had mean increases in HR of ≥10 bpm. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via: United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard Ireland HPRA Pharmacovigilance Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie e-mail: medsafety@hpra.ie Malta ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal 4.9 Overdose Effects of overdoses with exenatide (based on exenatide twice daily clinical studies) included severe nausea, severe vomiting and rapidly declining blood glucose concentrations. In the event of overdose, appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. 5. Pharmacological properties 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX04. Mechanism of action Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor in vitro, its mechanism of action mediated by cyclic AMP and/or other intracellular signaling pathways. Exenatide increases, on a glucose-dependent basis, the secretion of insulin from pancreatic beta cells. As blood glucose concentrations decrease, insulin secretion subsides. When exenatide was used in combination with metformin and/or a thiazolidinedione, no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin and/or a thiazolidinedione which may be due to this glucose-dependent insulinotropic mechanism (see section 4.4). Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes. Lower glucagon concentrations lead to decreased hepatic glucose output. However, exenatide does not impair the normal glucagon response and other hormone responses to hypoglycaemia. Exenatide slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation. Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety. Pharmacodynamic effects Exenatide improves glycaemic control through the sustained effects of lowering both postprandial and fasting glucose concentrations in patients with type 2 diabetes. Unlike native GLP-1, Bydureon has a pharmacokinetic and pharmacodynamic profile in humans suitable for once weekly administration. A pharmacodynamic study with exenatide demonstrated in patients with type 2 diabetes (n=13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose. Clinical efficacy and safety The results of long-term clinical studies of Bydureon are presented below; these studies comprised 1628 subjects (804 treated with Bydureon), 54 % men and 46 % women, 281 subjects (141 treated with Bydureon) were ≥ 65 years of age. Glycaemic control In two studies Bydureon 2 mg once weekly has been compared to exenatide twice daily 5 mcg for 4 weeks followed by exenatide twice daily 10 mcg. One study was of 24 weeks in duration (n= 252) and the other of 30 weeks (n= 295) followed by an open labelled extension where all patients were treated with Bydureon 2 mg once weekly for a further 22 weeks (n= 243). In both studies, decreases in HbA1c were evident in both treatment groups as early as the first post-treatment HbA1c measurement (weeks 4 or 6). Bydureon resulted in a statistically significant reduction in HbA1c compared to patients receiving exenatide twice daily (Table 2). A clinically relevant effect of Bydureon and exenatide twice-daily treated subjects was observed on HbA1c, regardless of the background anti-diabetic therapy in both studies. Clinically and statistically significantly more subjects on Bydureon compared to exenatide twice-daily patients achieved an HbA1c reduction of ≤ 7 % or < 7 % in the two studies (p < 0.05 and p=< 0.0001 respectively). Both Bydureon and exenatide twice daily patients achieved a reduction in weight compared to baseline, although the difference between the two treatment arms was not significant. Further reductions in HbA1c and sustained weight loss were observed for at least 52 weeks in the patients completing both the controlled 30-week study and the uncontrolled study extension. The evaluable patients who switched from exenatide twice daily to Bydureon (n= 121) achieved the same improvement in HbA1c of - 2.0 % , at the end of the 22 week extension compared to the initial baseline, as the patients treated with Bydureon for 52 weeks. Table 2: Results of two trials of Bydureon versus exenatide twice daily in combination with diet and exercise alone, metformin and/or sulphonylurea and metformin and/or thiazolidinedione (intent to treat patients).
A study of 26-week duration has been conducted, in which Bydureon 2 mg is compared to insulin glargine once daily. Bydureon demonstrated a superior change in HbA1c compared to insulin glargine. Compared with insulin glargine treatment, Bydureon treatment significantly lowered mean body weight and was associated with fewer hypoglycaemic events (Table 3). Table 3: Results of one 26 week trial of Bydureon versus insulin glargine in combination with metformin alone or metformin and sulphonylurea (intent to treat patients).
1 Insulin glargine was dosed to a target glucose concentration of 4.0 to 5.5 mmol/l (72 to 100 mg/dl). The mean dose of insulin glargine at the beginning of treatment was 10.1 IU/day rising to 31.1 IU/day for insulin glargine-treated patients. The 156-week results were consistent with those previously reported in the 26-week interim report. Treatment with Bydureon persistently significantly improved glycaemic control and weight control, compared to the insulin glargine treatment. Safety findings at 156 weeks were consistent with those reported at 26 weeks. In a 26-week double-blind study Bydureon was compared to maximum daily doses of sitagliptin and pioglitazone in subjects also using metformin. All treatment groups had a significant reduction in HbA1c compared to baseline. Bydureon demonstrated superiority to both sitagliptin and pioglitazone with respect to change in HbA1c from baseline. Bydureon demonstrated significantly greater weight reductions compared to sitagliptin. Patients on pioglitazone gained weight (Table 4). Table 4: Results of one 26-week trial of Bydureon versus sitagliptin and versus pioglitazone in combination with metformin (intent to treat patients).
Body weight A reduction in body weight compared to baseline has been observed in all Bydureon studies. This reduction in body weight was seen in patients treated with Bydureon irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction - 2.9 kg to - 5.2 kg with nausea versus - 2.2 kg to -2.9 kg without nausea). The proportion of patients who had both a reduction in weight and HbA1c ranged from 70 to 79 % (the proportion of patients who had a reduction of HbA1c ranged from 88 to 96 %). Plasma/serum glucose Treatment with Bydureon resulted in significant reductions in fasting plasma/serum glucose concentrations, these reductions were observed as early as 4 weeks. Additional reductions in postprandial concentrations were also observed. The improvement in fasting plasma glucose concentrations was durable through 52 weeks. Beta-cell function Clinical studies with Bydureon have indicated improved beta-cell function, using measures such as the homeostasis model assessments (HOMA-B). The durability of effect on beta-cell function was maintained through 52 weeks. Blood pressure A reduction in systolic blood pressure was observed in Bydureon studies (2.9 mmHg to 4.7 mmHg). In the 30 week exenatide twice daily comparator study both Bydureon and exenatide twice daily significantly reduced systolic blood pressure from base line (4.7±1.1 mmHg and 3.4±1.1 mmHg respectively) the difference between the treatments was not significant. Improvements in blood pressure were maintained through 52 weeks. Fasting lipids Bydureon has shown no adverse effects on lipid parameters. Paediatric population The European Medicines Agency has deferred the obligation to submit the results of studies with Bydureon in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 5.2 Pharmacokinetic properties The absorption properties of exenatide reflect the extended release properties of the Bydureon formulation. Once absorbed into the circulation, exenatide is distributed and eliminated according to its known systemic pharmacokinetic properties (as described in this section). Absorption Following weekly administration of 2 mg Bydureon, mean exenatide concentrations exceeded minimal efficacious concentrations (~ 50 pg/ml) in 2 weeks with gradual increase in the average plasma exenatide concentration over 6 to 7 weeks. Subsequently, exenatide concentrations of approximately 300 pg/ml were maintained indicating that steady-state was achieved. Steady-state exenatide concentrations are maintained during the one-week interval between doses with minimal peak to trough fluctuation from this average therapeutic concentration. Distribution The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is 28 l. Biotransformation and elimination Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. The mean apparent clearance of exenatide is 9 l/h. These pharmacokinetic characteristics of exenatide are independent of the dose. Approximately 10 weeks after discontinuation of Bydureon therapy, mean plasma exenatide concentrations fell below minimal detectable concentrations. Special populations Patients with renal impairment Population pharmacokinetic analysis of renal impaired patients receiving 2 mg Bydureon indicate that there may be an increase in systemic exposure of approximately 74 % and 23 % (median prediction in each group) in moderate (N=10) and mild (N=56) renal impaired patients, respectively as compared to normal (N=84) renal function patients. Patients with hepatic insufficiency No pharmacokinetic study has been performed in patients with hepatic insufficiency. Exenatide is cleared primarily by the kidney, therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide. Gender, race and body weight Gender, race and body weight have no clinically relevant influence on exenatide pharmacokinetics. Elderly patients Data in elderly are limited, but suggest no marked changes in exenatide exposure with increased age up to about 75 years old. In a pharmacokinetic study of exenatide twice daily in patients with type 2 diabetes, administration of exenatide (10 mcg) resulted in a mean increase of exenatide AUC by 36 % in 15 elderly subjects aged 75 to 85 years compared to 15 subjects aged 45 to 65 years likely related to reduced renal function in the older age group (see section 4.2). Paediatric population In a single-dose pharmacokinetic study of exenatide twice daily in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide (5 mcg) resulted in slightly lower mean AUC (16 % lower) and Cmax (25 % lower) compared to those observed in adults. No pharmacokinetics study of Bydureon has been conducted in the paediatric population. 5.3 Preclinical safety data Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity conducted with exenatide twice daily or Bydureon. In a 104-week carcinogenicity study with Bydureon a statistically significant increase in thyroid c - cell tumor incidence (adenomas and / or carcinomas) was observed in rats at all doses (1.4 - to 26 - fold the human clinical exposure with Bydureon). The human relevance of these findings is currently unknown. Animal studies with exenatide did not indicate harmful effects with respect to fertility; high doses of exenatide caused skeletal effects and reduced foetal and neonatal growth. 6. Pharmaceutical particulars 6.1 List of excipients Powder poly (D,L-lactide-co-glycolide) sucrose Solvent carmellose sodium sodium chloride polysorbate 20 sodium dihydrogen phosphate monohydrate disodium phosphate heptahydrate water for injections sodium hydroxide (for pH adjustment) 6.2 Incompatibilities In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products. 6.3 Shelf life 3 years The suspension must be injected immediately after mixing the powder and the solvent. 6.4 Special precautions for storage Store in a refrigerator (2°C - 8°C). Do not freeze. The pens may be kept for up to 4 weeks below 30°C prior to use. At the end of this period Bydureon should be used or discarded. Store in the original package in order to protect from light. For storage conditions after mixing of the medicinal product, see section 6.3. 6.5 Nature and contents of container Each dual-chamber pen contains exenatide powder and solvent in a Type 1 glass cartridge sealed at one end with a chlorobutyl rubber stopper and an aluminum seal, and at the other end with a chlorobutyl rubber piston. The two chambers are separated by a second chlorobutyl rubber piston. There is one needle supplied per pen. Each carton also contains one spare needle. Use only the supplied needles with the pen. Pack size of 4 single-dose pre-filled pens and a multipack containing 12 (3 packs of 4) single-dose pre-filled pens. Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling Pre-filled pen is for single-use only. The powder in one chamber must be mixed with the solvent in the other chamber of the pre-filled pen. The solvent should be visually inspected prior to use. The solvent should only be used if it is clear and free of particulate matter. After reconstitution, the mixture should only be used if it is white to off white and cloudy. Please see the package leaflet and Instructions for the User for additional information on suspension and administration. Use only the supplied custom needles with the pen. Bydureon must be injected subcutaneously immediately after mixing of the powder and the solvent. Bydureon that has been frozen must not be used. The patient should be instructed to discard the pen safely, with the needle still attached, after each injection. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 7. Marketing authorisation holder AstraZeneca AB SE-151 85 Södertälje Sweden 8. Marketing authorisation number(s) EU/1/11/696/003 4 pre-filled pens EU/1/11/696/004 3 x 4 pre-filled pens 9. Date of first authorisation/renewal of the authorisation 24th July 2014 10. Date of revision of the text 19th January 2015 Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection(http://www.medicines.org.uk/emc/medicine/24665) http://www.oneyao.net http://www.120ty.nt
|
Bydureon(艾塞那肽缓释注射用混悬液预充笔)简介:
英文药名:Bydureon(EXENATIDE injection in pre-filled pen)
中文药名:艾塞那肽缓释剂注射用混悬液预充笔
生产厂家:Amylin Pharmaceuticals,Inc./Alkermes plc药品介绍Bydureon为长效注射剂。艾 ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多
|